Literature DB >> 7897308

Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells.

R S Fife1, G W Sledge.   

Abstract

Metastatic disease is one of the major causes of death from cancer in human beings. Several enzyme systems have been implicated in the metastatic process, but the metalloproteinases (MPs) appear to be the major group involved in most instances of neoplastic invasion. Increased MP activity has been correlated with the metastatic potential of many cancers, including breast cancer. MPs also play a role in tumor angiogenesis. Tetracyclines are antimicrobial agents that can suppress MP activity in a variety of tissues, including gingiva, bone, and cartilage. Several reports have indicated that tetracyclines can suppress tumor MPs as well. A synthetic tetracycline, doxycycline, inhibits migration of human MDA-MB-435 breast adenocarcinoma cells through a reconstituted basement membrane (Matrigel), an assay used as an in vitro surrogate for the in vivo process of tumor invasion through basement membranes. Additionally, doxycycline diminishes the proliferation of this breast cancer cell line and also decreases its gelatinolytic activity, as determined by gel zymography.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7897308

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  23 in total

Review 1.  Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

Authors:  M T Labro
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Effects of chemically modified tetracyclines (CMTs) in sensitive, multidrug resistant and apoptosis resistant leukaemia cell lines.

Authors:  M Tolomeo; S Grimaudo; S Milano; M La Rosa; V Ferlazzo; G Di Bella; C Barbera; D Simoni; P D'Agostino; E Cillari
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 3.  Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers.

Authors:  Bal L Lokeshwar
Journal:  Pharmacol Res       Date:  2010-11-18       Impact factor: 7.658

4.  Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells.

Authors:  Q Meng; J Xu; I D Goldberg; E M Rosen; R A Greenwald; S Fan
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

5.  SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells.

Authors:  Emily Young; Lucio Miele; Kevan B Tucker; Min Huang; Jeremy Wells; Jian-Wei Gu
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

6.  Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration.

Authors:  Jianhua S Yao; Fanxia Shen; William L Young; Guo-Yuan Yang
Journal:  Neurochem Int       Date:  2006-12-04       Impact factor: 3.921

7.  Preclinical trial on the use of doxycycline for the treatment of adenocarcinoma of the duodenum.

Authors:  Hector R Galván-Salazar; Alejandro D Soriano-Hernández; Daniel A Montes-Galindo; Gabriel Ceja Espíritu; José Guzman-Esquivel; Iram P Rodríguez-Sánchez; Oscar A Newton-Sánchez; Margarita L Martinez-Fierro; Xóchitl G Briseño Gómez; Augusto Rojas-Martínez; Iván Delgado-Enciso
Journal:  Mol Clin Oncol       Date:  2016-09-08

Review 8.  Toward checkmate: biology and breast cancer therapy for the new millennium.

Authors:  K D Miller; G W Sledge
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

9.  A nonantibiotic chemically modified tetracycline (CMT-3) inhibits intimal thickening.

Authors:  Muzharul M Islam; Christopher D Franco; David W Courtman; Michelle P Bendeck
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

10.  Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer.

Authors:  Suresh Kumar; Hiromitsu Kishimoto; Hui Lin Chua; Sunil Badve; Kathy D Miller; Robert M Bigsby; Harikrishna Nakshatri
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.